Loading...
Market
Retro Biosciences achieves 10-year lifespan extension in human trials by end of 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Official reports from Retro Biosciences or peer-reviewed publications
Story
OpenAI's GPT-4b Micro Model Enhances Yamanaka Factors for Longevity Research with Retro Biosciences
Jan 17, 2025, 07:28 PM
OpenAI has developed a new AI model named GPT-4b micro in collaboration with Retro Biosciences, a longevity research company, to enhance the efficiency of stem cell production. The model focuses on re-engineering Yamanaka factors, a set of proteins that can transform regular cells into stem cells. According to OpenAI, the model's suggestions have led to modifications of two Yamanaka factors, increasing their effectiveness by more than 50 times in preliminary tests. This project marks OpenAI's first foray into biological data modeling and aims to contribute to scientific discovery in longevity science. Retro Biosciences, funded by OpenAI CEO Sam Altman with $180 million, seeks to extend human lifespan by 10 years through such research. The collaboration is intended to demonstrate OpenAI's commitment to advancing science, though the model is not yet available for public use.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Amazon • 25%
Google • 25%
Other • 25%
Microsoft • 25%
Q1 2025 • 25%
Q3 2025 • 25%
Q4 2025 • 25%
Q2 2025 • 25%
No • 50%
Yes • 50%
Negative effects or halted trials • 25%
Proven effective with significant lifespan extension • 25%
No significant effect on lifespan • 25%
Proven effective with moderate lifespan extension • 25%
$100 million to $200 million • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
More than $200 million • 25%
More than $300 million • 25%
$200 million to $300 million • 25%
$100 million to $200 million • 25%
Less than $100 million • 25%